Dental Care Clinics in Vernon, NJ Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Jackson Jeong Dds Llc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 521 County Route 515, Unit 3 And 4, Vernon, NJ 07462 Phone: 617-834-0237 |
Vernon Dental Arts, Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 249 State Rt 94, Vernon, NJ 07462 Phone: 973-827-3400 Fax: 973-827-3364 |
Vernon Dental Associates Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 248 Route 94, Vernon, NJ 07462 Phone: 973-827-5455 |
Alpha & Omega Dental Of Nj, Llp Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 6 Church St., Vernon, NJ 07462 Phone: 973-764-7483 |
News Archive
New understanding on insulin resistance, action of diabetes drugs may lead to safer medication
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Study on aspirin may offer hope to develop drugs that promote healing of chronic wounds in humans
In addition to its known capacity to promote bleeding events, aspirin also inhibits wound healing. New research published in The Journal of Experimental Medicine now describes how aspirin acts on key skin cells called keratinocytes, delaying skin repair at wound sites.
Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint
Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
NPS Pharmaceuticals closes public offering of 7,912,000 common stock shares
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
› Verified 4 days ago